Acquisition History / CorMedix Inc. / Melinta Therapeutics LLC
CorMedix Inc. Acquires Melinta Therapeutics LLC
Announced September 2, 2025 — $300M
What happened
Melinta Therapeutics is a private commercial-stage company with seven marketed hospital acute care and infectious disease products including MINOCIN, REZZAYO and VABOMERE. CorMedix completed the acquisition September 2, 2025, paying $300M upfront comprising $260M in cash and the balance in stock.
- Acquirer
- CorMedix Inc.
- Target
- Melinta Therapeutics LLC
- Announced
- September 2, 2025
- Price
- $300M
- Industry
- Specialty hospital pharmaceuticals
- Buyer type
- Strategic acquirer
- Status
- Closed
By the numbers
Frequently Asked Questions About This Acquisition
When did CorMedix Inc. acquire Melinta Therapeutics LLC?
CorMedix Inc. acquired Melinta Therapeutics LLC on September 2, 2025. This was CorMedix Inc.'s 1st publicly tracked acquisition out of 1 we have on record.
How much did CorMedix Inc. pay for Melinta Therapeutics LLC?
CorMedix Inc. paid $300M for Melinta Therapeutics LLC.
What does Melinta Therapeutics LLC do?
Melinta Therapeutics is a private commercial-stage company with seven marketed hospital acute care and infectious disease products including MINOCIN, REZZAYO and VABOMERE. CorMedix completed the acquisition September 2, 2025, paying $300M upfront comprising $260M in cash and the balance in stock.
What other Specialty hospital pharmaceuticals companies has CorMedix Inc. acquired?
Melinta Therapeutics LLC is CorMedix Inc.'s only publicly tracked acquisition in Specialty hospital pharmaceuticals so far.